Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2026-03-09 @ 2:15 AM
Study NCT ID:
NCT04793958
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-11
First Post:
2021-03-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Sponsor:
Mirati Therapeutics Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA239-0006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None